Amisulpride 100mg/ml Sugar Free Oral Solution

Summary of Product Characteristics Updated 25-Jan-2022 | Thame Laboratories

1. Name of the medicinal product

Amisulpride 100mg/ml Sugar Free Oral Solution

2. Qualitative and quantitative composition

The active substance is amisulpride.

Each ml of oral solution contains 100mg of amisulpride.

Excipients with known effect:

Each ml of oral solution contains 1.2mg methyl parahydroxybenzoate (E218).

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Oral Solution

A clear, pale yellow colour solution with caramel odour.

4. Clinical particulars
4.1 Therapeutic indications

Amisulpride is indicated for the treatment of schizophrenic disorders.

4.2 Posology and method of administration

As a general recommendation; Amisulpride can be administered once a day at oral doses up to 400 mg, higher dose should be split into two separate doses

For acute psychotic episodes: Oral doses between 4 ml/day (400 mg/day) and 8 ml/day (800 mg/day) are recommended. In individual cases, the daily dose may be increased up to 12 ml/day (1200 mg/day). Doses above 12 ml/day (1200 mg/day) have not been extensively evaluated for safety and therefore should not be used. No specific titration is required when initiating the treatment with Amisulpride. Doses should be adjusted according to individual response.

Maintenance treatment should be established individually with the minimally effective dose.

For patients characterised by predominant negative symptoms: Oral doses between 0.5 ml/day (50 mg/day) and 3 ml/day (300 mg/day) are recommended. Doses should be adjusted individually.

The minimum effective dose should be used.

Elderly: The safety of amisulpride has been examined in a limited number of elderly patients. Amisulpride should be used with particular caution because of a possible risk of hypotension and sedation. Reduction in dosage may also be required because of renal insufficiency.

Children: The efficacy and safety of amisulpride from puberty to the age of 18 years have not been established. There are limited data available on the use of amisulpride in adolescents in schizophrenia. Therefore, the use of amisulpride from puberty to the age of 18 years is not recommended; in children up to puberty amisulpride is contraindicated, as its safety has not yet been established (see section 4.3).

Renal insufficiency: Amisulpride is eliminated by the renal route. In renal insufficiency, the dose should be reduced to half in patients with creatinine clearance (CRCL) between 30-60 ml/min and to a third in patients with CRCL between 10-30 ml/min. As there is no experience in patients with severe renal impairment (CRCL < 10 ml/min) particular care is recommended in these patients (see section 4.4).

Hepatic insufficiency: since the drug is weakly metabolised a dosage reduction should not be necessary.

Method of administration

For oral use only.

The oral solution should be drunk with a liquid, which does not contain alcohol.

4.3 Contraindications

• Hypersensitivity to the active ingredient or to other ingredients of the medicinal product listed in section 6.1.

• Concomitant prolactin-dependent tumours (e.g. pituitary gland prolactinomas or breast cancer) (see section 4.4 and section 4.8)

• Phaeochromocytoma

• Children under 15

• Combination with

- Dopaminergics other than parkinson's (cabergoline and quinagolide)

- citalopram, escitalopram, domperidone, hydroxyzine, piperaquine (see section 4.5)

4.4 Special warnings and precautions for use

Neuroleptic Malignant Syndrome:

As with other neuroleptics, Neuroleptic Malignant Syndrome, a potentially fatal complication, characterized by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated CPK, may occur. In the event of hyperthermia, particularly with high daily doses, all antipsychotic drugs including Amisulpride should be discontinued.


Hyperglycaemia has been reported in patients treated with some atypical antipsychotic agents, including amisulpride, therefore patients with an established diagnosis of diabetes mellitus or with risk factors for diabetes who are started on amisulpride, should get appropriate glycaemic monitoring.

Renal insufficiency:

Amisulpride is eliminated by the renal route. In cases of renal insufficiency, the dose should be decreased or intermittent treatment could be considered (see section 4.2).


Amisulpride may lower the seizure threshold. Therefore patients with a history of epilepsy should be closely monitored during Amisulpride therapy.

Elderly patients:

In elderly patients, Amisulpride, like other neuroleptics, should be used with particular caution because of a possible risk of hypotension or sedation. Reduction in dosage may also be required because of renal insufficiency.

Parkinson's disease:

As with other antidopaminergic agents, caution should be also exercised when prescribing Amisulpride to patients with Parkinson's disease since it may cause worsening of the disease. Amisulpride should be used only if neuroleptic treatment cannot be avoided.

Withdrawal symptom:

Acute withdrawal symptoms including nausea, vomiting and insomnia, have very rarely been described after abrupt cessation of high doses of antipsychotic drugs. Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported. Therefore, gradual withdrawal of amisulpride is advisable.

Prolongation of the QT interval:

Caution should be exercised when amisulpride is prescribed in patients with known cardiovascular disease or family history of QT prolongation and concomitant use with neuroleptics should be avoided.

This effect, known to potentiate the risk of occurrence of serious ventricular rhythm disorders, in particular with torsade de point type, is increased by the existence of bradychardia, hypokalemia with long congenital QT (combination with a drug that increases the QTc interval) (see section 4.8)

It is therefore advisable, when the clinical situation allows, to make sure before any administration of the absence of factors that may favor the occurrence of this rhythm disorder:

• Bradycardia less than 55 beats per minute,

• hypokalemia,

• congenital prolongation of the QT interval,

• treatment in progress with a medicinal product liable to cause marked bradycardia (<55 beats per minute), hypokalemia, slowing of the intracardiac conduction, lengthening of the QTc interval (see sections 4.3 and 4.5).

It is recommended to perform an ECG in the initial assessment of patients to be treated long term with a neuroleptic


In randomized clinical trials versus placebo performed in a population of elderly patients with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase of the risk of cerebrovascular events has been observed. The mechanism of such risk increase is not known. An increase in the risk with other antipsychotic drugs, or other populations of patients cannot be excluded. Amisulpride should be used with caution in patients with stroke risk factors.

Elderly patients with dementia:

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death in clinical trials with atypical antipsychotics were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality.

The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.

Venous thromboembolism:

Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Amisulpride and preventive measures undertaken.

Breast cancer:

Amisulpride may increase prolactin levels. Therefore, caution should be exercised and patients with a history or a family history of breast cancer should be closely monitored during Amisulpride therapy.

Benign pituitary tumour:

Amisulpride may increase prolactin levels. Cases of benign pituitary tumours such as prolactinoma have been observed during amisulpride therapy (see section 4.8). In case of very high levels of prolactin or clinical signs of pituitary tumour (such as visual field defect and headache), pituitary imaging should be performed. If the diagnosis of pituitary tumour is confirmed, the treatment with amisulpride must be stopped (see section 4.3).


Severe liver toxicity has been reported with the use of amisulpride. Patients should be informed of the need to report signs such as asthenia, anorexia, nausea, vomiting, abdominal pain or jaundice immediately to a doctor. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately (see section 4.8)

Blood and Lymphatic system disorders:

Leukopenia, neutropenia and agranulocytosis have been reported with antipsychotics, including Amisulpride. Unexplained infections or fever may be evidence of blood dyscrasia (see section 4.8), and requires immediate haematological investigation.


Amisulpride is not recommended in combination with alcohol, dopaminergic antiparkinsonians, antiparasitics likely to give torsades de pointes, methadone, levodopa and other neuroleptics and other medicines likely to give torsades de pointes, sodium oxybate and hydroxychloroquine (see section 4.5).

Excipients warnings

This product contains methyl parahydroxybenzoate (E218), which may cause allergic reactions (possibly delayed).

4.5 Interaction with other medicinal products and other forms of interaction

Sedative drugs

It must be taken into account that many drugs or substances can add their depressant effects to the central nervous system and help to decrease alertness. These are morphine derivatives (analgesics, cough suppressants and substitution treatments), neuroleptics, barbiturates, benzodiazepine, anxiolytics other than benzodiazepines (for example, meprobamate), hypnotics, sedative antidepressants (amitriptyline, doxepin, mianserin, mirtazapine, trimipramine), sedative H1 antihistamines, central antihypertensives, baclofen and thalidomide.

Drugs that may cause torsades de pointes

This severe heart rhythm disorder can be caused by a number of medications including antiarrhythmics and medicines which induce Hypokalaemia (see hypokalaemia drugs). Hypokalaemia is a favouring factor of Torsadas de pointes as are bradycardia inducing drugs (see bradycardia causing drugs) or a pre-existing lengthening of the QT interval, congenital or acquired. The drugs causing the side effect include class Ia and III antiarrhythmics, some neuroleptics. Other molecules that do not belong to these classes are also involved. For dolasetron, erythromycin, spiramycin and vincamine, only the form administered intravenously are affected by this interaction.

The use of a drug which may cause Torsades de pointes with other drugs which may cause Torsades de pointes is generally contra indicated. However, some of them, due to their unavoidable nature, are an exception to the rule, being only not recommended with other drugs which may cause Torsade de points. These are methadone, hydroxychloroquine, antiparasitics (chloroquine, halofantrine, lumefantrine, pentamidine) and neuroleptics. However, citalopram, escitalopram, domperidone, hydroxyzine and piperaquine are contraindicated with all drugs which may cause Torsades de pointes

Contraindicated combinations

• Dopaminergics other than parkinson's (cabergoline, quinagolide) mutual antagonism of dopamine agonist and neuroleptics.

• Combination with citalopram, escitalopram, domperidone, hydroxyzine, piperaquine

Increased risk of ventricular rhythm disorders, especially torsade de pointes.

Combinations not recommended

Antiparasitics likely to give torsades de pointes (chloroquine, halofantrine, lumefantrine, pentamidine)

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

If possible, stop one of the two treatments.

If the combination cannot be avoided, prior control of the QT and monitored ECG monitoring.

Dopaminergic anti-Parkinson drugs (amantadine, apomorphine, bromocriptine, entacapone, lisuride, pergolide, piribedil, pramiprexole, rasagiline, ropinirole, rotigotine, selegiline, tolcapone)

Reciprocal antagonism of dopaminergic and neuroleptics.

The dopaminergic can cause or worsen psychotic disorders. If treatment with neuroleptics is necessary in the parkinsonian patient treated with dopaminergics, the latter must be gradually reduced until stopping (their sudden cessation exposes them to a risk of "neuroleptic malignant syndrome").

Other drugs likely to give torsades de pointes: antiarrhythmic drugs class Ia (quinidine, hydroquinidine, disopyramide) and class III (amiodarone, dronedarone, sotalol, dofetilide, ibutilide), and other drugs such as arsenieux, diphé manil, dolasetron IV, erythromycin IV, levofloxacin, mequitazine, mizolastine, prucalopride, vincamine IV, moxifloxacin, spiramycin IV, toremifene, vandetanib

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

• Other neuroleptics likely to give torsades de pointes (chlorpromazine, cyamemazine, droperidol, flupenthixol, fluphenazine, haloperidol, levomepromazine, pimozide, pipamperone, pipotiazine, sulpiride, sultopride, tiapride, zuclopenthixol)

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

• Alcohol (drink or excipient)

Increase by alcohol of the sedative effect of these substances.

Impaired alertness can make driving and using machines dangerous.

Avoid taking alcoholic beverages and drugs containing alcohol.

• Levodopa

Reciprocal antagonism of levodopa and neuroleptics.

In the Parkinson's patient, use effective minimum doses of each of the two drugs.

• Methadone

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

• Sodium oxybate

Increase in central depression. Impaired alertness can make driving and using machines dangerous.

• Hydroxychloroquine

Increased risk of ventricular rhythm disturbances, especially torsade de pointes.

Combination subject to precautions for use

• Anagrelide

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

Clinical and electrocardiographic monitoring during the association.

• Azithromycin, ciprofloxacin, clarithromycin, levofloxacin, norfloxacin, roxithromycin

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

Clinical and electrocardiographic monitoring during the association.

• Beta blockers in heart failure (bisoprolol, carvedilol, metoprolol, nebivolol)

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

In addition, vasodilator effect and risk of hypotension, especially orthostatic (additive effect).

Clinical monitoring and electrocardiograph.

• Bradycardisants (in particular class Ia antiarrhythmics, beta-blockers, certain class III antiarrhythmics, certain calcium antagonists, digitalis, pilocarpine, anticholinesterases)

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

Clinical and electrocardiographic monitoring.

• Hypokalemic drugs (hypokalemic diuretics, alone or in combination, stimulant laxatives, glucocorticoids, tetracosactide and amphotericin B IV)

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

Correct any hypokalemia before administering the product and carry out clinical, electrolytic and electrocardiographic monitoring.

• Lithium

Risk of developing neuropsychic signs suggestive of a neuroleptic malignant syndrome or lithium intoxication. Regular clinical and biological monitoring, especially at the start of association.

• Ondansetron

Increased risk of ventricular rhythm disturbances, especially torsades de pointes.

Clinical and electrocardiographic monitoring during the association.

Combination to take into account

• Other sedative drugs

Increase in central depression.

Impaired alertness can make driving and using machines dangerous.

• Orlistat

Risk of therapeutic failure in case of concomitant treatment with orlistat

4.6 Fertility, pregnancy and lactation


There are limited data from the use of amisulpride in pregnant women. The safety of the use of amisulpride during pregnancy has not been established. Amisulpride crosses the placenta. Studies in animals have shown toxicity to reproductive function (see section 5.3). The use of Amisulpride is not recommended during pregnancy and in women of childbearing potential not using effective contraception, unless the expected benefits justify the potential risks involved. Newborns exposed to antipsychotics (including amisulpride) during the third trimester of pregnancy, are at risk of adverse events including extrapyramidal symptoms and / or withdrawal symptoms, which may vary in severity and duration after birth (see section 4.8). The following reactions have been reported: agitation, hypertonia, hypotonia, tremors, drowsiness, respiratory distress, eating disorders. As a result, newborns should be closely monitored.


Amisulpride is excreted in breast milk in a fairly large amount, in some cases exceeding the accepted value of 10% of the dosage adjusted for the weight of the mother, but the concentrations in the blood in breast-fed infants have not been evaluated. There is insufficient information on the effects of amisulpride in newborns / infants. You should decide whether to stop breastfeeding or not take amisulpride taking into account the benefit of breastfeeding for the child and the benefit of the treatment for the woman.


A decrease in fertility linked to the pharmacological effects of the drug (prolactin-dependent effect) has been observed in treated animals.

4.7 Effects on ability to drive and use machines

Attention is drawn, in particular to drivers of vehicles and users of machines, to the risk of drowsiness and blurred vision associated with the use of this medicine (see section 4-8).

4.8 Undesirable effects

Adverse effects have been ranked under headings of frequency using the following convention: very common (≥ 1/10); common (≥ 1/100; <1/10); uncommon (≥ 1/1,000; <1/100); rare (≥ 1/10,000; <1/1,000); very rare (<1/10,000); frequency not known (cannot be estimated from the available data).

Clinical trials data

The following adverse effects have been observed in controlled clinical trials. It should be noted that in some instances it can be difficult to differentiate adverse events from symptoms of the underlying disease.

MedDRA organ system class


Adverse drug reactions

Nervous system disorders

Very common

Extrapyramidal symptoms may occur: tremor, rigidity, hypokinesia, hypersalivation, akathisia, dyskinesia. These symptoms are generally mild at optimal dosages and partially reversible without discontinuation of amisulpride upon administration of antiparkinsonian medication. The incidence of extrapyramidal symptoms which is dose related, remains very low in the treatment of patients with predominantly negative symptoms with doses of 50-300 mg/day.


Acute dystonia (spasm torticollis, oculogyric crisis, trismus) may appear. This is reversible without discontinuation of amisulpride upon treatment with an antiparkinsonian agent. Somnolence.


Tardive dyskinesia characterized by rhythmic, involuntary movements primarily of the tongue and/or face have been reported, usually after long term administration. Antiparkinsonian medication is ineffective or may induce aggravation of the symptoms. Seizures.

Psychiatric disorders


Insomnia, anxiety, agitation, orgasmic dysfunction

Gastrointestinal disorders


Constipation, nausea, vomiting, dry mouth

Endocrine disorders


Amisulpride causes an increase in plasma prolactin levels which is reversible after drug discontinuation. This may result in galactorrhoea, amenorrhoea, gynaecomastia, breast pain, and erectile dysfunction.

Metabolism and nutrition disorders


Hyperglycemia (see section 4.4).

Cardiovascular disorders







Weight gain


Elevations of hepatic enzymes, mainly transaminases

Immune system disorders


Allergic reaction

Post-Marketing data

In addition, cases of the following adverse reactions have been reported through spontaneous reporting only:

MedDRA organ system class


Adverse drug reactions

Blood and Lymphatic system disorders


Leukopenia, neutropenia (see section 4.4)



Endocrine disorders


Benign pituitary tumour such as prolactinoma (see section 4.3 and 4.4)

Metabolism and nutrition disorders


Hypertriglyceridemia and hypercholesterolemia


Hyponatraemia, syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Psychiatric disorders



Nervous system disorders


Neuroleptic Malignant Syndrome (see section 4.4), which is a potentially fatal complication

Frequency not known

Restless leg syndrome.

Eye disorders


Blurred vision (see Section 4.7)

Cardiac disorders


QT interval prolongation and ventricular arrhythmias such as torsade de pointes, ventricular tachycardia, which may result in ventricular fibrillation or cardiac arrest, sudden death (see section 4.4).

Vascular disorders

Frequency not known

Cases of venous thromboembolism, including cases of pulmonary embolism, sometimes fatal, and cases of deep vein thrombosis have been reported with antipsychotic drugs.


Increase in blood pressure

Skin and subcutaneous tissue disorders


Angioedema, urticaria

Frequency not known

Photosensitivity reaction.

Musculoskeletal and connective tissue disorders


Osteopenia, osteoporosis

Pregnancy, puerperium and perinatal conditions

Frequency not known

Drug withdrawal syndrome neonatal (see section 4.6)

Respiratory, thoracic and mediastinal disorders


Nasal congestion


inhalation pneumonia (mainly in combination with other antipsychotics and central nervous system depressant drugs).

Hepatobiliary disorders


Hepatocellular injury

Kidney and urinary tract disorders


Urinary retention

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website at: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Experience with Amisulpride in overdosage is limited. Exaggeration of the known pharmacological effects of the drug have been reported. These include drowsiness and sedation, coma, hypotension and extrapyramidal symptoms. Fatal outcomes have been reported mainly in combination with other psychotropic agents.

In cases of acute overdosage, the possibility of multiple drug intake should be considered.

Since Amisulpride is weakly dialysed, hemodialysis is of no use to eliminate the drug.

There is no specific antidote to Amisulpride.

Appropriate supportive measures should therefore be instituted with close supervision of vital functions including continuous cardiac monitoring due to the risk of prolongation of the QT interval until the patient recovers.

If severe extrapyramidal symptoms occur, anticholinergic agents should be administered.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antipsychotics, ATC code: N05A L05

Amisulpride binds selectively with a high affinity to human dopaminergic D2/D3 receptor subtypes whereas it is devoid of affinity for D1, D4 and D5 receptor subtypes.

Unlike classical and atypical neuroleptics, amisulpride has no affinity for serotonin, adrenergic, histamine H1 and cholinergic receptors. In addition, amisulpride does not bind to sigma sites.

In animal studies, at high doses, amisulpride blocks dopamine receptors located in the limbic structures in preference to those in the striatum.

At low doses it preferentially blocks pre-synaptic D2/D3 receptors, producing dopamine release responsible for its disinhibitory effects.

This pharmacological profile explains the clinical efficacy of Amisulpride against both negative and positive symptoms of schizophrenia.

5.2 Pharmacokinetic properties


In man, amisulpride shows two absorption peaks: one which is attained rapidly, one hour post-dose and a second between 3 and 4 hours after administration. Corresponding plasma concentrations are 39 ± 3 and 54 ± 4 ng/ml after a 50 mg dose. Absolute bioavailability is 48%.

A carbohydrate rich meal (containing 68% fluids) significantly decreases the AUCs, Tmax and Cmax of amisulpride but no changes were seen after a high fat meal. However, the significance of these findings in routine clinical use is not known.


The volume of distribution is 5.8 l/kg, plasma protein binding is low (16%) and no drug interactions are suspected.


Amisulpride is weakly metabolised: two inactive metabolites, accounting for approximately 4% of the dose, have been identified. There is no accumulation of amisulpride and its pharmacokinetics remain unchanged after the administration of repeated doses.


Amisulpride is eliminated unchanged in the urine. Fifty percent of an intravenous dose is excreted via the urine, of which 90% is eliminated in the first 24 hours. Renal clearance is in the order of 20 l/h or 330 ml/min. The elimination half-life of amisulpride is approximately 12 hours after an oral dose.

Hepatic insufficiency:

Since the drug is weakly metabolised a dosage reduction should not be necessary in patients with hepatic insufficiency.

Renal insufficiency:

The elimination half-life is unchanged in patients with renal insufficiency while systemic clearance is reduced by a factor of 2.5 to 3. The AUC of amisulpride in mild renal failure increased two fold and almost tenfold in moderate renal failure (see section 4.2). Experience is however limited and there is no data with doses greater than 50 mg.

Amisulpride is very weakly dialysed.


Limited pharmacokinetic data in elderly subjects (> 65 years) show that a 10-30 % rise occurs in Cmax, T1/2 and AUC after a single oral dose of 50 mg. No data are available after repeat dosing.

5.3 Preclinical safety data

An overall review of the completed safety studies indicates that Amisulpride is devoid of any general, organ-specific, teratogenic, mutagenic or carcinogenic risk. Changes observed in rats and dogs at doses below the maximum tolerated dose are either pharmacological effects or are devoid of major toxicological significance under these conditions. Compared with the maximum recommended dosages in man, maximum tolerated doses are 2 and 7 times greater in the rat (200 mg/kg/day) and dog (120 mg/kg/day) respectively in terms of AUC. No carcinogenic risk, relevant to man, was identified in the rat at up to 1.5 to 4.5 times the expected human AUC.

A mouse carcinogenicity study (120 mg/kg/day) and reproductive studies (160, 300 and 500 mg/kg/day respectively in rat, rabbit and mouse) were performed. The exposure of the animals to amisulpride during these latter studies was not evaluated.

6. Pharmaceutical particulars
6.1 List of excipients

Saccharin sodium (E954)

Sodium gluconate (E576)

Glucono-delta-lactone (E575)

Hydrochloric acid, concentrated (E507)

Methyl parahydroxybenzoate (E218)

Caramel flavour (containing propylene glycol (E1520))

Purified water

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

24 months

Discard 60 days after first opening.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

For storage conditions after first opening of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Bottle: Ph.Eur. Type III amber glass bottle

Closure: Child resistant, tamper evident plastic (polyethylene/polypropylene) cap with EPE liner

Dosing Device: 5ml oral syringe with 0.5ml graduation

Pack Size: 60ml

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Syri Limited,

Unit 4, Bradfield Road,

Ruislip, Middlesex,


Trading as:

Thame Laboratories,

Unit 4, Bradfield Road,

Ruislip, Middlesex,



Trading as:


Unit 4, Bradfield Road,

Ruislip, Middlesex,

HA4 0NU, UK.

8. Marketing authorisation number(s)

PL 39307/0070

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 07 December 2016

Common Renewal date: 06 December 2021

10. Date of revision of the text


Company Contact Details
Thame Laboratories

Unit 4, Bradfield Road, Ruislip, Middlesex, HA4 0NU

Medical Information Direct Line

0330 1359 422

Customer Care direct line

+44 (0)208 515 3700



+44 (0)208 515 3700

Medical Information e-mail
Stock Availability

+44 (0)208 515 3700